US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients with paroxysmal atrial fibrillation (AF) as the company looks to expand ...
Original Image Link
Source:www.msn.com
Original Image Link
Source:www.msn.com
Posted: 2025-01-20 12:56:00